Hormone therapy combined with GLP-1 drug may support weight loss during menopause
Postmenopausal women may achieve greater weight loss by combining hormone therapy with tirzepatide, a GLP-1-based obesity medication, according to a ...
Postmenopausal women may achieve greater weight loss by combining hormone therapy with tirzepatide, a GLP-1-based obesity medication, according to a ...
Australia is projected to face a $90 billion annual obesity crisis by 2032 while currently spending below the OECD average ...
Health and Human Services Secretary Robert F. Kennedy Jr. criticized Starbucks and Dunkin' for the high sugar content in their ...
Novo Nordisk announced it will reduce the prices of its weight-loss drugs Wegovy and Ozempic by up to 50%, effective ...
Drugmaker Eli Lilly and Co. Announces $3.5 Billion Facility in PennsylvaniaEli Lilly plans to construct a $3.5 billion manufacturing facility ...
Health Canada is reviewing nine submissions for generic versions of semaglutide, the active ingredient in Novo Nordisk's weight loss drugs ...
The World Health Organization (WHO) has recommended the use of GLP-1 drugs for obesity management in adults, marking a significant ...
Those seeking to emigrate to the US now face stricter visa restrictions, with the Trump administration targeting overweight applicants who ...
Eli Lilly (NYSE: LLY) is the world's most valuable healthcare stock, valued at over $760 billion, largely due to its ...
Obesity has overtaken undernourishment to become the leading form of malnutrition among children and teenagers globally, with nearly 10% of ...
Copyright © 2026 News Wave
News Wave is not responsible for the content of external sites.